Dizal Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company showing a loss of 210 million yuan. The company's total operating revenue was 523 million yuan, and net cash outflow from operating activities was 274 million yuan, an increase of 9.6384 million yuan compared with the same period last year. The latest asset-liability ratio was 60.35%, up 1.35 percentage points from the previous quarter and up 10.96 percentage points from the same period last year. Gross margin was 96.00%, return on equity was negative 18.62%, and diluted earnings per share was negative 0.45 yuan. The company had 12,900 shareholders, and the top ten shareholders held 316 million shares, accounting for 67.87% of total share capital.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. ANet loss of 210 million yuan in interim report
